326 related articles for article (PubMed ID: 22411078)
1. The role of therapeutic apheresis in the treatment of acute antibody-mediated kidney rejection.
Ahmed T; Senzel L
J Clin Apher; 2012; 27(4):173-7. PubMed ID: 22411078
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
3. Prevention and treatment of alloantibody-mediated kidney transplant rejection.
Bartel G; Schwaiger E; Böhmig GA
Transpl Int; 2011 Dec; 24(12):1142-55. PubMed ID: 21831227
[TBL] [Abstract][Full Text] [Related]
4. Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale.
Fehr T; Gaspert A
Transpl Int; 2012 Jun; 25(6):623-32. PubMed ID: 22394269
[TBL] [Abstract][Full Text] [Related]
5. Characterization of rejection episodes in patients following positive crossmatch and ABO-incompatible live donor renal transplantation.
Kayler LK; Farber JL; Colombe B; LaCava D; Friedewald JJ; Ratner LE
Transpl Int; 2006 Feb; 19(2):128-39. PubMed ID: 16441362
[TBL] [Abstract][Full Text] [Related]
6. Significance of low-level DSA detected by solid-phase assay in association with acute and chronic antibody-mediated rejection.
Hirai T; Kohei N; Omoto K; Ishida H; Tanabe K
Transpl Int; 2012 Sep; 25(9):925-34. PubMed ID: 22764746
[TBL] [Abstract][Full Text] [Related]
7. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
Gupta G; Abu Jawdeh BG; Racusen LC; Bhasin B; Arend LJ; Trollinger B; Kraus E; Rabb H; Zachary AA; Montgomery RA; Alachkar N
Transplantation; 2014 Jun; 97(12):1240-6. PubMed ID: 24937198
[TBL] [Abstract][Full Text] [Related]
8. Treatment of acute antibody-mediated rejection: a single-center experience.
Rodríguez Ferrero M; Rincón A; Bucalo L; Rementería A; Anaya F
Transplant Proc; 2010 Oct; 42(8):2848-50. PubMed ID: 20970547
[TBL] [Abstract][Full Text] [Related]
9. Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation.
Brown CM; Abraham KA; O'Kelly P; Conlon PJ; Walshe JJ
Transplant Proc; 2009 Nov; 41(9):3690-2. PubMed ID: 19917368
[TBL] [Abstract][Full Text] [Related]
10. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
Hardinger KL; Murillo D
Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
[TBL] [Abstract][Full Text] [Related]
11. [Role of antibodies in kidney transplant].
Ruffoni E; Seveso M; Marson P; Tison T; Cozzi E
G Ital Nefrol; 2012; 29 Suppl 54():S54-60. PubMed ID: 22388831
[TBL] [Abstract][Full Text] [Related]
12. Antibody-mediated rejection: treatment alternatives and outcomes.
Singh N; Pirsch J; Samaniego M
Transplant Rev (Orlando); 2009 Jan; 23(1):34-46. PubMed ID: 19027615
[TBL] [Abstract][Full Text] [Related]
13. Deciphering antibody-mediated rejection: new insights into mechanisms and treatment.
Stegall MD; Gloor JM
Curr Opin Organ Transplant; 2010 Feb; 15(1):8-10. PubMed ID: 19890210
[TBL] [Abstract][Full Text] [Related]
14. Treatment of antibody-mediated rejection including immunoadsorption during first year after renal transplantation--Clinical results and regulation of endothelial progenitor cells.
Opgenoorth M; Wagner A; Passauer J; Hohenstein B; Hugo C
Atheroscler Suppl; 2015 May; 18():67-73. PubMed ID: 25936307
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of immunoadsorption to reduce donor-specific alloantibodies in kidney-transplant candidates.
Rostaing L; Congy N; Aarnink A; Maggioni S; Allal A; Sallusto F; Game X; Kamar N
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():201-6. PubMed ID: 25894155
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic features and treatment response of early acute antibody-mediated rejection in Thai kidney transplant recipients: a single-center experience.
Larpparisuth N; Vongwiwatana A; Vareesangthip K; Cheunsuchon B; Parichatikanon P; Premasathian N
Transplant Proc; 2014; 46(2):474-6. PubMed ID: 24655992
[TBL] [Abstract][Full Text] [Related]
17. [Indications for apheresis in kidney transplant recipients: apheresis in the hyperimmune patient].
Busnach G; Di Leo L
G Ital Nefrol; 2012; 29 Suppl 54():S22-6. PubMed ID: 22388825
[TBL] [Abstract][Full Text] [Related]
18. [Antibody-mediated acute rejection].
Lefaucheur C; Nochy D; Glotz D
Nephrol Ther; 2008 Oct; 4 Suppl 3():S188-91. PubMed ID: 19000885
[TBL] [Abstract][Full Text] [Related]
19. Indicators of treatment responsiveness to rituximab and plasmapheresis in antibody-mediated rejection after kidney transplantation.
Immenschuh S; Zilian E; Dämmrich ME; Schwarz A; Gwinner W; Becker JU; Blume CA
Transplantation; 2015 Jan; 99(1):56-62. PubMed ID: 25121474
[TBL] [Abstract][Full Text] [Related]
20. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.
Fehr T; Rüsi B; Fischer A; Hopfer H; Wüthrich RP; Gaspert A
Transplantation; 2009 Jun; 87(12):1837-41. PubMed ID: 19543061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
